Does the media refer more to GANX or LYEL?

In the previous week, Lyell Immunopharma had 8 more articles in the media than Gain Therapeutics. MarketBeat recorded 11 mentions for Lyell Immunopharma and 3 mentions for Gain Therapeutics. Lyell Immunopharma's average media sentiment score of 0.75 beat Gain Therapeutics' score of 0.64 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GANX or TENX more profitable?

Tenax Therapeutics' return on equity of -56.32% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Tenax Therapeutics N/A -56.32% -53.12%

Is ELDN or GANX more profitable?

Eledon Pharmaceuticals' return on equity of -116.97% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Gain Therapeutics N/A -201.44% -136.24%

Does the media refer more to ELDN or GANX?

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 3 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.84 beat Gain Therapeutics' score of 0.64 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NLTX or GANX?

Gain Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 389.91%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is NLTX or GANX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Gain Therapeutics N/A -201.44% -136.24%

Gain Therapeutics (GANX) Competitors

$1.74 +0.06 (+3.27%)

As of 10:04 AM Eastern

Compare

GANX vs. LYEL, BCYC, TENX, ELDN, and NLTX

Should you buy Gain Therapeutics stock or one of its competitors? MarketBeat compares Gain Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gain Therapeutics include Lyell Immunopharma (LYEL), Bicycle Therapeutics (BCYC), Tenax Therapeutics (TENX), Eledon Pharmaceuticals (ELDN), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.

How does Gain Therapeutics compare to Lyell Immunopharma?

Gain Therapeutics (NASDAQ:GANX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Gain Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Lyell Immunopharma had 8 more articles in the media than Gain Therapeutics. MarketBeat recorded 11 mentions for Lyell Immunopharma and 3 mentions for Gain Therapeutics. Lyell Immunopharma's average media sentiment score of 0.75 beat Gain Therapeutics' score of 0.64 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has higher revenue and earnings than Lyell Immunopharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,479.96	-$20.16M	-$0.58	N/A
Lyell Immunopharma	$31K	10,504.06	-$274.45M	-$13.80	N/A

Gain Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 389.91%. Lyell Immunopharma has a consensus target price of $43.00, indicating a potential upside of 208.13%. Given Gain Therapeutics' higher probable upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Gain Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Summary

Lyell Immunopharma beats Gain Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Gain Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Gain Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Gain Therapeutics	N/A	-201.44%	-136.24%

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gain Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.89	-$218.96M	-$3.15	N/A
Gain Therapeutics	$50K	1,479.96	-$20.16M	-$0.58	N/A

In the previous week, Gain Therapeutics had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Gain Therapeutics' score of 0.64 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Gain Therapeutics	Positive

Bicycle Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 245.25%. Gain Therapeutics has a consensus price target of $8.50, indicating a potential upside of 389.91%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bicycle Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Summary

Bicycle Therapeutics beats Gain Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Tenax Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gain Therapeutics has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,479.96	-$20.16M	-$0.58	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

In the previous week, Gain Therapeutics had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.43 beat Gain Therapeutics' score of 0.64 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Positive
Tenax Therapeutics	Positive

Gain Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Tenax Therapeutics' return on equity of -56.32% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Gain Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 389.91%. Tenax Therapeutics has a consensus target price of $39.67, indicating a potential upside of 243.97%. Given Gain Therapeutics' higher possible upside, equities research analysts plainly believe Gain Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Gain Therapeutics beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Eledon Pharmaceuticals' return on equity of -116.97% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Gain Therapeutics	N/A	-201.44%	-136.24%

Eledon Pharmaceuticals currently has a consensus price target of $9.67, indicating a potential upside of 170.47%. Gain Therapeutics has a consensus price target of $8.50, indicating a potential upside of 389.91%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Gain Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Gain Therapeutics	$50K	1,479.96	-$20.16M	-$0.58	N/A

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 3 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.84 beat Gain Therapeutics' score of 0.64 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Summary

Gain Therapeutics beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Gain Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 389.91%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Neoleukin Therapeutics' return on equity of -37.22% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Gain Therapeutics	N/A	-201.44%	-136.24%

In the previous week, Gain Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 0 mentions for Neoleukin Therapeutics. Gain Therapeutics' average media sentiment score of 0.64 beat Neoleukin Therapeutics' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Gain Therapeutics	Positive

Gain Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Gain Therapeutics	$50K	1,479.96	-$20.16M	-$0.58	N/A

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Summary

Gain Therapeutics beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$73.36M	$2.99B	$6.49B	$12.31B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-2.97	18.81	24.05	24.76
Price / Sales	1,479.96	468.63	542.61	168.32
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	3.61	4.01	10.69	6.90
Net Income	-$20.16M	$75.79M	$3.57B	$337.45M
7 Day Performance	2.66%	2.78%	1.56%	2.84%
1 Month Performance	-0.86%	0.52%	2.49%	4.78%
1 Year Performance	0.29%	24.68%	26.51%	33.08%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	2.1744 of 5 stars	$1.74 +3.3%	$8.50 +389.9%	-2.9%	$73.36M	$50K	N/A	20
LYEL Lyell Immunopharma	2.9916 of 5 stars	$12.70 +3.2%	$43.00 +238.6%	+38.6%	$287.24M	$40K	N/A	270	Analyst Forecast
BCYC Bicycle Therapeutics	3.7594 of 5 stars	$4.17 +1.5%	$14.00 +235.7%	-51.6%	$286.92M	$72.86M	N/A	240	Positive News High Trading Volume
TENX Tenax Therapeutics	3.0819 of 5 stars	$10.73 +1.8%	$29.67 +176.5%	+101.4%	$279.58M	N/A	N/A	9	Positive News Analyst Forecast Gap Up High Trading Volume
ELDN Eledon Pharmaceuticals	1.7558 of 5 stars	$3.55 -0.8%	$9.67 +172.3%	+24.4%	$276.33M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. LYEL, BCYC, TENX, ELDN, and NLTX

How does Gain Therapeutics compare to Lyell Immunopharma?

Summary

How does Gain Therapeutics compare to Bicycle Therapeutics?

Summary

How does Gain Therapeutics compare to Tenax Therapeutics?

Summary

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Gain Therapeutics compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. LYEL, BCYC, TENX, ELDN, and NLTX

How does Gain Therapeutics compare to Lyell Immunopharma?

Which has more risk and volatility, GANX or LYEL?

Do insiders and institutionals believe in GANX or LYEL?

Does the media refer more to GANX or LYEL?

Which has stronger earnings & valuation, GANX or LYEL?

Do analysts prefer GANX or LYEL?

Is GANX or LYEL more profitable?

Summary

How does Gain Therapeutics compare to Bicycle Therapeutics?

Is BCYC or GANX more profitable?

Do institutionals & insiders believe in BCYC or GANX?

Which has higher valuation & earnings, BCYC or GANX?

Does the media refer more to BCYC or GANX?

Do analysts rate BCYC or GANX?

Which has more risk & volatility, BCYC or GANX?

Summary

How does Gain Therapeutics compare to Tenax Therapeutics?

Do institutionals and insiders believe in GANX or TENX?

Which has higher earnings & valuation, GANX or TENX?

Does the media refer more to GANX or TENX?

Which has more volatility and risk, GANX or TENX?

Is GANX or TENX more profitable?

Do analysts recommend GANX or TENX?

Summary

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Is ELDN or GANX more profitable?

Do analysts recommend ELDN or GANX?

Which has preferable earnings & valuation, ELDN or GANX?

Does the media refer more to ELDN or GANX?

Do institutionals and insiders believe in ELDN or GANX?

Which has more risk & volatility, ELDN or GANX?

Summary

How does Gain Therapeutics compare to Neoleukin Therapeutics?

Do institutionals & insiders hold more shares of NLTX or GANX?

Do analysts prefer NLTX or GANX?

Is NLTX or GANX more profitable?

Does the media prefer NLTX or GANX?

Which has better earnings and valuation, NLTX or GANX?

Which has more risk & volatility, NLTX or GANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools